A new Inserm Transfert Technology Offers experience coming soon in April !

CHIM14143-T1

G quadruplex ligands to treat infectious diseases

The present inventions relate to
– metallated porphyrin derivatives as ligands of G quadruplex and their use as anti-viral agents. Porphyrin derivatives candidates inhibits HIV replication with IC 50 around 100 nM in vitro.
More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle;
-methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one G4 forming sequence oligonucleotide;
– novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV) , Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus (KSHV). In particular, the invention relates to novel compound derivatives that are shown to be G-quadruplex ligands and are thus useful for treating the above infections. Also the invention relates to the process of preparation of the novel compound derivatives.


Keywords : Virology, HIV, G4-Quadruplex, Ebola
Patent Application number : EP15 306 737.6
Patent Application date : 2015-10-30
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : -
Inventors : ANDREOLA
Samir AMRANE
Jean-Louis MERGNY
Geneviève PRATVIEL
Publications :
  • Biochimie. 2015 Nov;118:173-5. doi: 10.1016/j.biochi.2015.09.009. Epub 2015 Sep 10.
  • Review Nucleic Acids Res. 2014 Nov 10;42(20):12352-66. doi: 10.1093/nar/gku999. Epub 2014 Oct 20.
  • Dalton Trans. 2019 May 7;48(18):6091-6099. doi: 10.1039/c8dt04703k.

Related offers


The 10 Last viewed

You haven't seen any form yet.